Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539) FDA DailyMed (current GLP-1 prescribing information) Mayo Clinic Prescription weight-loss drugs MeAgain App Store listing What MeAgain users say about tracking GLP-1 What Our Users Say I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication
On Monday, Novo Nordisk said it is suing Hims, asking the court to permanently ban the company from selling compounded versions of its drugs that infringe on Novos patents
and it reduces oxidative stress in melanocytes, which is a key driver of hyperpigmentation
doi: 10.3389/fimmu.2025.1542735 Received 10 December 2024 Accepted 09 April 2025 Published 01 May 2025 Volume 16 - 2025 Edited by Ana Sanches Silva, National Institute for Agricultural and Veterinary Research (INIAV), Portugal Reviewed by Brandon Marc Lane, Duke University, United States Ujjawal Sharma, Central University of Punjab, India Munkhtuya Tumurkhuu, Wake Forest Baptist Medical Center, United States Updates Copyright 2025 Jechel, Nedelcu, Dragan, Lupu, Starcea, Mocanu, Rosu, Streanga, Russu, Baciu, Danielescu, Salaru, Morariu, Cirstea, Anton and Lupu